GLP1 receptor Agonists—effects beyond obesity and diabetes
SS Wilbon, MG Kolonin - Cells, 2023 - mdpi.com
Glucagon-like peptide-1 receptor agonists (GLP1RA) have been transformative for patients
and clinicians in treating type-2 diabetes and obesity. Drugs of this class, the bioavailability …
and clinicians in treating type-2 diabetes and obesity. Drugs of this class, the bioavailability …
[HTML][HTML] The Potential of Anti-Inflammatory DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus
A typical consequence of type 2 diabetes mellitus, diabetic kidney disease (DKD) is a
significant risk factor for end-stage renal disease. The pathophysiology of diabetic kidney …
significant risk factor for end-stage renal disease. The pathophysiology of diabetic kidney …
The benefits of GLP-1 drugs beyond obesity
DJ Drucker - Science, 2024 - science.org
Glucagon-like peptide–1 (GLP-1) is secreted from gut endocrine cells in response to food
ingestion and acts as an incretin hormone to potentiate glucose-dependent insulin …
ingestion and acts as an incretin hormone to potentiate glucose-dependent insulin …
Impact of hyperglycemia on immune cell function: a comprehensive review
Hyperglycemia, a hallmark of diabetes and various metabolic disorders, has profound
implications for immune cell function. The relationship between elevated blood glucose …
implications for immune cell function. The relationship between elevated blood glucose …
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care
Aims/hypothesis We compared the effects of sodium–glucose cotransporter 2 (SGLT2)
inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on renal …
inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on renal …
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
HM Colhoun, I Lingvay, PM Brown, J Deanfield… - Nature Medicine, 2024 - nature.com
The SELECT trial previously reported a 20% reduction in major adverse cardiovascular
events with semaglutide (n= 8,803) versus placebo (n= 8,801) in patients with …
events with semaglutide (n= 8,803) versus placebo (n= 8,801) in patients with …
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
A Mazzieri, F Porcellati, F Timio, G Reboldi - International Journal of …, 2024 - mdpi.com
Diabetic kidney disease (DKD) is a chronic microvascular complication in patients with
diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD) …
diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD) …
GLP-1 Agonism for Kidney Transplant Recipients: A Narrative Review of Current Evidence and Future Directions Across the Research Spectrum
VJ Riehl-Tonn, KD Medak… - … Journal of Kidney …, 2024 - journals.sagepub.com
Purpose of Review: Diabetes is the most common cause of kidney disease in individuals
that receive a kidney transplant, and those without pre-existing diabetes are at greater risk of …
that receive a kidney transplant, and those without pre-existing diabetes are at greater risk of …
[HTML][HTML] Mechanism and therapeutic targets of circulating immune cells in diabetic retinopathy
B Zhao, Y Zhao, X Sun - Pharmacological Research, 2024 - Elsevier
Diabetic retinopathy (DR) continues to be the leading cause of preventable vision loss
among working-aged adults, marked by immune dysregulation within the retinal …
among working-aged adults, marked by immune dysregulation within the retinal …
[HTML][HTML] Unraveling diabetic kidney disease: the roles of mitochondrial dysfunction and immunometabolism
P Narongkiatikhun, YJ Choi, H Hampson… - Kidney International …, 2024 - Elsevier
Mitochondria are essential for cellular energy production and are implicated in numerous
diseases, including diabetic kidney disease (DKD). Current evidence indicates that …
diseases, including diabetic kidney disease (DKD). Current evidence indicates that …